September 28, 2021
Cranbury, New Jersey--IVIEW Therapeutics Inc., an innovative specialty biotechnology company committed to becoming a leader in ophthalmic therapeutics, announced the closing of its A+ round financing of approximately $25 million USD from both new and existing investors. This round was led by Proxima Ventures Fund, and also included new investors Cowin Capital, Ningbo Jiufeng Capital, Guangzhou Junyuan Capital, Hangzhou Naxin Capital, Haitian (HK) Co., PA Bioadvance, and existing investors including Shenzhen Share Capital, Zhejiang Huahai Pharmaceutical and Alpha Bioventure LLC. . This round was over-subscribed as its original plan aimed to raise $20 million dollars.
Dr. Bo Liang, Chairman & CEO at IVIEW commented, "I am glad that the investors, both new and existing participants, have confidence in IVIEW’s team, its ophthalmic drug delivery platform technologies and product pipeline. We plan to use the proceeds from this round of investment to complete IVIEW-1201’s global phase II trials, as a potential first-line treatment of viral conjunctivitis, and to advance the company’s preclinical assets into clinical development for dry eye and the treatment of cataracts. IVIEW is also aggressively pursuing business development opportunities for innovative developmental assets.
“We are happy to lead this round of investment into IVIEW Therapeutics, followed by other reputable venture groups. We are impressed by IVIEW’s team and its product pipeline to bring various ophthalmic products to clinical development. We hope the company will invest in innovative products to fulfill unmet medical needs.” Commented by Mr. Luke Sun, Founding Partner of Proxima Venture.
About IVIEW Therapeutics Inc.
IVIEW Therapeutics Inc. is a clinical-stage specialty biotechnology company focusing on innovative ophthalmic therapeutics. IVIEW is headquartered at 5 Cedar Brook Drive, Cranbury, NJ (the greater-Princeton area). IVIEW was founded by experienced pharmaceutical veterans and clinical ophthalmologists to help patients by bringing novel ophthalmic drug products to market to address unmet medical needs. Please visit: www.iviewtherapeutics.com for more details.
2021年9月28日，克兰伯里，新泽西州——艾威药业，一家致力于成为眼科治疗领域领导者的创新型专业生物技术公司，宣布完成来自新老投资者约为2500万美元的A+轮融资。此轮融资由比邻星创投Proxima Ventures基金领投，也包括了新的投资者同创伟业、宁波久沣、广州浚源、杭州纳新、海天（香港）控股有限公司、PA Bioadvance和现有的投资者包括深圳分享资本、浙江华海药业和Alpha Bioventure LLC.这一轮融资超额完成了原定的2000万美元的融资目标。
艾威药业联合创始人、董事长兼首席执行官梁波博士评论说：“我很高兴新老投资者对艾威团队、艾威的眼科给药平台技术和产品管线充满信心。我们计划将投资款项用于完成病毒性结膜炎的一线治疗药物IVIEW-1201的全球二期试验。和将公司的临床前项目包括治疗干眼症和白内障治疗的一类和二类新药推进到临床开发。同时艾威药业还在全球积极寻求创新业务的发展机会， 引进创新临床开发阶段药物。
"我们很高兴领投艾威药业的这一轮投资， 而且获得其他知名风险投资集团的跟投。我们对艾威的专业团队，及其将各种眼科创新产品推向临床开发的丰富的产品管线印象深刻。我们也期待公司投资创新产品以解决未被满足的医疗迫切需求。”比邻星创投创始合伙人孙晓璐先生如此说。
关于艾威药业
艾威药业是一家专注于创新眼科药物开发的处于临床开发阶段的专业生物技术公司。艾威药业总部位于美国新泽西州大普林斯顿地区5 Cedar Brook Drive, Cranbury, New Jersey。艾威药业是由经验丰富的制药资深专家和临床眼科医生创立，旨在通过开发创新眼科药物产品推向市场来解决该治疗类别中未被满足的迫切临床医疗需求。
详情请浏览：www.iviewtherapeutics.com 和www.iview-cn.com。
语言：